Low Intensity Focused Ultrasound for Binge Eating Disorder

Last updated: December 16, 2025
Sponsor: Ali Rezai
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Bulimia

Binge Eating Disorder

Treatment

LIFU Neuromodulation

Clinical Study ID

NCT06485687
RNI_NMD_BED01
  • Ages 22-65
  • All Genders

Study Summary

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with Binge Eating Disorder (BED)

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Males and non-pregnant females, 22 - 65 years of age.

  • Participant meets DSM-5 criteria for moderate to extreme BED.

  • Weight ≤450lb to accommodate in MRI.

  • Shoulder width of ≤65 inches to accommodate in MRI.

  • The neuromodulation targets are visible on MRI for target selection.

  • Participant is able and willing to give informed consent.

Exclusion

Exclusion Criteria:

  • Unable to undergo MR-imaging because of implanted pacemakers, medication pumps,aneurysm clips, metallic prostheses (including metal pins and rods, heart valves orcochlear implants), shrapnel fragments, permanent make-up or small metal fragmentsin the eye that welders and other metal workers may have, or if candidates areuncomfortable in small spaces (have claustrophobia).

  • Participants with more than 30% of the skull area traversed by the sonicationpathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp,or implanted objects in the skull or the brain.

  • Participants with known untreated or unstable cardiac status or hypertension

  • Evidence of substance (alcohol or other drug) use disorder during the previous 12months (assessed via SCID-5).

  • Past or present diagnosis of schizophrenia, psychotic disorder or bipolar disorder (assessed via SCID-5)

  • Participant who is currently participating in another clinical investigation with anactive treatment arm.

  • Use of any medications that, in the opinion of the Investigator, may put theparticipant at higher risk for AEs, or impair the participant's ability to performcomplete study procedures.

  • Participant is considered to be a poor surgical or study candidate, which mayinclude, but is not limited to the following: any medical, social, or psychologicalproblem that could complicate the required procedures and evaluations of the studyin the judgment of the investigator.

  • Participant is pregnant/lactating or planning to be pregnant.

Study Design

Total Participants: 15
Treatment Group(s): 1
Primary Treatment: LIFU Neuromodulation
Phase:
Study Start date:
October 31, 2024
Estimated Completion Date:
December 31, 2027

Study Description

The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for BED

Connect with a study center

  • West Virginia University: Rockefeller Neuroscience Institute

    Morgantown, West Virginia 26506
    United States

    Site Not Available

  • West Virginia University: Rockefeller Neuroscience Institute

    Morgantown 4815352, West Virginia 4826850 26506
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.